{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:47:17Z","timestamp":1770835637755,"version":"3.50.1"},"reference-count":58,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T00:00:00Z","timestamp":1558310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Science"],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Anti\u2010<jats:styled-content style=\"fixed-case\">PUF<\/jats:styled-content>60 autoantibodies are reportedly detected in the sera of patients with dermatomyositis and Sj\u00f6gren's syndrome; however, little is known regarding its existence in the sera of cancer patients. <jats:styled-content style=\"fixed-case\">FIR<\/jats:styled-content>, a splicing variant of the <jats:italic><jats:styled-content style=\"fixed-case\">PUF<\/jats:styled-content>60<\/jats:italic> gene, is a transcriptional repressor of <jats:italic>c\u2010myc<\/jats:italic>. In colorectal cancer, there is an overexpression of the dominant negative form of <jats:styled-content style=\"fixed-case\">FIR<\/jats:styled-content>, in which exon 2 is lacking (<jats:styled-content style=\"fixed-case\">FIR<\/jats:styled-content>\u0394exon2). Previously, large\u2010scale <jats:styled-content style=\"fixed-case\">SEREX<\/jats:styled-content> (serological identification of antigens by recombinant <jats:styled-content style=\"fixed-case\">cDNA<\/jats:styled-content> expression cloning) screenings have identified anti\u2010<jats:styled-content style=\"fixed-case\">FIR<\/jats:styled-content> autoantibodies in the sera of cancer patients. In the present study, we revealed the presence and significance of anti\u2010<jats:styled-content style=\"fixed-case\">FIR<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">FIR<\/jats:styled-content>\/<jats:styled-content style=\"fixed-case\">FIR<\/jats:styled-content>\u0394exon2) Abs in the sera of patients with esophageal squamous cell carcinoma (<jats:styled-content style=\"fixed-case\">ESCC<\/jats:styled-content>). Our results were validated by an amplified luminescence proximity homogeneous assay using sera of patients with various cancer types. We revealed that anti\u2010<jats:styled-content style=\"fixed-case\">FIR<\/jats:styled-content>\u0394exon2 Ab had higher sensitivity than anti\u2010<jats:styled-content style=\"fixed-case\">FIR<\/jats:styled-content> Ab. Receiver operating characteristic (ROC) analysis was applied for evaluating the use of anti\u2010<jats:styled-content style=\"fixed-case\">FIR<\/jats:styled-content>\u0394exon2 Ab as candidate markers such as anti\u2010p53 Ab and carcinoembryonic antigen, and the highest area under the <jats:styled-content style=\"fixed-case\">ROC<\/jats:styled-content> curve was observed in the combination of anti\u2010<jats:styled-content style=\"fixed-case\">FIR<\/jats:styled-content>\u0394exon2 Ab and anti\u2010p53 Ab. In summary, our results suggest the use of anti\u2010<jats:styled-content style=\"fixed-case\">FIR<\/jats:styled-content>\u0394exon2 Ab in combination with the anti\u2010p53 Ab as a predictive marker for <jats:styled-content style=\"fixed-case\">ESCC<\/jats:styled-content>. The area under the ROC curve was further increased in the advanced stage of <jats:styled-content style=\"fixed-case\">ESCC<\/jats:styled-content>. The value of anti\u2010<jats:styled-content style=\"fixed-case\">FIR<\/jats:styled-content>\u0394exon2 autoantibody as novel clinical indicator against <jats:styled-content style=\"fixed-case\">ESCC<\/jats:styled-content> and as a companion diagnostic tool is discussed.<\/jats:p>","DOI":"10.1111\/cas.14024","type":"journal-article","created":{"date-parts":[[2019,4,13]],"date-time":"2019-04-13T18:19:38Z","timestamp":1555179578000},"page":"2004-2013","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Anti\u2010<scp>FIR<\/scp>\u0394exon2, a splicing variant form of <scp>PUF<\/scp>60, autoantibody is detected in the sera of esophageal squamous cell carcinoma"],"prefix":"10.1111","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6152-177X","authenticated-orcid":false,"given":"Sohei","family":"Kobayashi","sequence":"first","affiliation":[{"name":"Department of Frontier Surgery Graduate School of Medicine Chiba University Chiba Japan"},{"name":"Department of Laboratory Medicine &amp; Division of Clinical Genetics and Proteomics Chiba University Hospital Chiba Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaki","family":"Hiwasa","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Genetics, Graduate School of Medicine Chiba University Chiba Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Ishige","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine &amp; Division of Clinical Genetics and Proteomics Chiba University Hospital Chiba Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bahityar","family":"Rahmutulla","sequence":"additional","affiliation":[{"name":"Department of Molecular Oncology, Graduate School of Medicine Chiba University Chiba Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Kano","sequence":"additional","affiliation":[{"name":"Department of Frontier Surgery Graduate School of Medicine Chiba University Chiba Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tyuji","family":"Hoshino","sequence":"additional","affiliation":[{"name":"Department of Physical Chemistry, Graduate School of Pharmaceutical Sciences Chiba University Chiba Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshinari","family":"Minamoto","sequence":"additional","affiliation":[{"name":"Kanazawa University, Cancer Research Institute Division of Translational and Clinical Oncology Ishikawa Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideaki","family":"Shimada","sequence":"additional","affiliation":[{"name":"Department of Gastroenterological Surgery, Graduate School of Medicine Toho University Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumio","family":"Nomura","sequence":"additional","affiliation":[{"name":"Divisions of Clinical Mass Spectrometry and Clinical Genetics Chiba University Hospital Chiba Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisahiro","family":"Matsubara","sequence":"additional","affiliation":[{"name":"Department of Frontier Surgery Graduate School of Medicine Chiba University Chiba Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyuki","family":"Matsushita","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine &amp; Division of Clinical Genetics and Proteomics Chiba University Hospital Chiba Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,5,20]]},"reference":[{"key":"e_1_2_8_2_1","first-page":"1472","article-title":"Esophageal carcinoma","volume":"372","author":"Rustgi A","year":"2015","journal-title":"N Engl J Med"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21208"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60643-6"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2935"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.25.11810"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20517"},{"key":"e_1_2_8_8_1","first-page":"463","article-title":"Identification of a novel SEREX antigen, SLC2A1\/GLUT1, in esophageal squamous cell carcinoma","volume":"28","author":"Kuboshima M","year":"2006","journal-title":"Int J Oncol"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2006.00192.x"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-9-232"},{"key":"e_1_2_8_11_1","first-page":"77","article-title":"Serological identification of tumor antigens of esophageal squamous cell carcinoma","volume":"26","author":"Shimada H","year":"2005","journal-title":"Int J Oncol"},{"key":"e_1_2_8_12_1","first-page":"97","article-title":"Serum anti\u2010myomegalin antibodies in patients with esophageal squamous cell carcinoma","volume":"30","author":"Shimada H","year":"2007","journal-title":"Int J Oncol"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-5956-9-31"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.2741\/3461"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(02)00738-9"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.270.14.8241"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.16.6.2656"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.200800322"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23051"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/21541264.2017.1293595"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(01)00223-9"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2011.01931.x"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2015.84"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-4459"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0000538"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1355838299991938"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-018-4031-4"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207509"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24963"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12696"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.20517\/2394-5079.2018.81"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.25149"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12058"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.5794\/jjoms.36.307"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s005950170093"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-015-0393-4"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.23789"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756-9966-31-85"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.23653"},{"key":"e_1_2_8_40_1","first-page":"49","article-title":"Association of serum antibody levels against TUBB2C with diabetes and cerebral infarction","volume":"1","author":"Hiwasa T","year":"2015","journal-title":"Integ Biomed Sci"},{"key":"e_1_2_8_41_1","first-page":"2","article-title":"Identification of cerebral infarction\u2010specific antibody markers from autoantibodies detected in patients with systemic lupus erythematosus","volume":"6","author":"Goto K","year":"2015","journal-title":"J Mol Biomark Diagnos"},{"key":"e_1_2_8_42_1","first-page":"097","article-title":"Elevated levels of autoantibodies against ATP2B4 and BMP\u20101 in sera of patients with atherosclerosis\u2010related diseases","volume":"11","author":"Hiwasa T","year":"2015","journal-title":"Immunome Res"},{"key":"e_1_2_8_43_1","first-page":"1001","article-title":"An anti\u2010deoxyhypusine synthase antibody as a marker of atherosclerosis\u2010related cerebral infarction, myocardial infarction, diabetes mellitus, and chronic kidney disease","volume":"1","author":"Nakamura R","year":"2017","journal-title":"SM Atheroscler J"},{"key":"e_1_2_8_44_1","first-page":"132","article-title":"Serum SH3BP5\u2010specific antibody level is a biomarker of atherosclerosis","volume":"13","author":"Hiwasa T","year":"2017","journal-title":"Immunome Res"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0810641105"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2007.03.027"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.2307\/2531595"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1109\/LSP.2014.2337313"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-12-77"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341X.2000.01134.x"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1650"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.12-207639"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2013.07.011"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2012.10.010"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.125732"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M004671200"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ydbio.2011.10.027"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0601083103"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells7090124"}],"container-title":["Cancer Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcas.14024","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.14024","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cas.14024","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cas.14024","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,10]],"date-time":"2023-09-10T19:13:55Z","timestamp":1694373235000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cas.14024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,20]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["10.1111\/cas.14024"],"URL":"https:\/\/doi.org\/10.1111\/cas.14024","archive":["Portico"],"relation":{},"ISSN":["1347-9032","1349-7006"],"issn-type":[{"value":"1347-9032","type":"print"},{"value":"1349-7006","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,20]]},"assertion":[{"value":"2019-02-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}